AACE

🎙️ New podcast episode! Vin Tangpricha, MD, PhD, MACE, moderates a discussion with Janet McGill, MD, MA, FACP, MACE, and Amy C. Donihi, PharmD, BC-ADM, FCCP, on the 2026 AACE Consensus Statement: Use of Diabetes Technology for Management of Adults with Diabetes.
Listen now: pro.aace.com/podcast/episod…

#WeAreAACE

A GPCR-specific model reduced false-positive GLP-1 receptor variant predictions by approximately 78% in validation testing, offering new possibilities for precision endocrinology.
aaceendocrine.ai/articles/2026/…

@JohnsonThomasMD

TODAY: Complimentary Diagnosing and Managing Severe Hypertriglyceridemia in Familial Chylomicronemia Syndrome Webinar 🗓 Nov 6 | ⏰ 1–2 PM EST
• FCS vs. common hyperTG—clinical & genetic insights
• Pancreatitis risk reduction & QoL strategies
• RNA-based & team-based therapies
Endocrinologists & care teams—register before we start! 🔗 pro.aace.com/education-and-…

#WeAreAACE

🚨 Today at 12 PM EST: Complimentary webinar- Diagnosis, Treatment Selection, and Monitoring of Growth Hormone Deficiency in Adults. Earn credits as experts cover diagnosis, therapy selection & monitoring. Join live 👉pro.aace.com/education-and-…

#WeAreAACE

For those new to injectable diabetes and obesity medications such as Ozempic (semaglutide) and Zepbound (tirzepatide), this article shares safe self-injection tips, with Dace L. Trence, MD, MACE, president of AACE, emphasizing careful vial-and-syringe techniques to avoid dosing issues from air bubbles and the need to clearly label sharps containers. Learn more tips: everydayhealth.com/obesity/glp-1-….

#WeAreAACE